Neuren Pharmaceuticals Limited Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
8/10/2012 9:51:31 AM
More...
|
Noble Life Sciences Inc. Announces Collaboration With Perseis Therapeutics -- Noble to Manage Neuren Pharmaceuticals Limited Subsidiary's Oncology Program
7/10/2012 8:19:55 AM
More...
|
Neuren Pharmaceuticals Limited Holds Pre-IND Meeting on Proposed Rett Syndrome Clinical Trials With FDA
5/17/2012 8:21:22 AM
More...
|
Neuren Pharmaceuticals Limited To Get US$5.5M Additional Funding for US Army Clinical Trial of NNZ-2566
9/5/2008 9:44:14 AM
More...
|
Neuren Pharmaceuticals Limited Announce Glypromate(R) and NNZ-2566 Included in 10 Most Promising Neuroscience Projects by Windhover Information Inc.
7/21/2008 9:21:31 AM
More...
|
Neuren Pharmaceuticals Limited Raises A$7.1M in Rights Issue
2/11/2008 12:07:00 PM
More...
|
US Department of Defense Approves Funding for Neuren Pharmaceuticals Limited NNZ-2566 Trials
1/21/2008 11:16:20 AM
More...
|
Neuren Pharmaceuticals Limited Announces A$10.1 Million Non-Renounceable Rights Issue
12/19/2007 10:34:21 AM
More...
|
Neuren Pharmaceuticals Limited Completes NNZ-2566 Phase 1b Safety Trial
11/7/2007 2:07:20 PM
More...
|
Neuren Pharmaceuticals Limited in First Phase 3 Trial in Australia
9/26/2007 1:16:07 PM
More...
|
|